Sector News

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

March 17, 2015
Life sciences
/PRNewswire/ – Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ across a range of therapeutic applications, announced today that Tal Zaks, M.D., Ph.D., will join Moderna’s executive leadership team as chief medical officer, effective March 16.
 
Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.
 
“Moderna holds an unprecedented financial position among pre-clinical biotech companies, with $900 million on its balance sheet and strategic agreements with three industry leaders: AstraZeneca, Alexion and Merck,” said Stephane Bancel, chief executive officer of Moderna. “As we prepare to initiate several clinical trials in the coming quarters, we require an exceptional chief medical officer, someone with a track record of success in clinical development combined with strong business acumen. Tal is that leader. He has a unique ability to think outside the box and execute for business results. We are delighted that he chose to join Moderna.”
 
“I am thrilled to be joining Moderna and be at the forefront of translating innovative science into real medicines for patients,” said Dr. Zaks. “I’ve been impressed with the potential of messenger RNA Therapeutics to expand and accelerate drug development for a wide range of unmet medical needs and I look forward to working with the leadership team, our partners and our ventures to fulfill this vision.”
 
Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.
 
Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
 
Source: Moderna Therapeutics

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]